BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 24217135)

  • 1. The influence of BRCA1/BRCA2 mutations on toxicity related to chemotherapy and radiotherapy in early breast cancer patients.
    Huszno J; Budryk M; Kołosza Z; Nowara E
    Oncology; 2013; 85(5):278-82. PubMed ID: 24217135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.
    Kriege M; Seynaeve C; Meijers-Heijboer H; Collee JM; Menke-Pluymers MB; Bartels CC; Tilanus-Linthorst MM; Blom J; Huijskens E; Jager A; van den Ouweland A; van Geel B; Hooning MJ; Brekelmans CT; Klijn JG
    J Clin Oncol; 2009 Aug; 27(23):3764-71. PubMed ID: 19564533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Familial breast cancer: clinical response to induction chemotherapy or radiotherapy related to BRCA1/2 mutations status.
    Fourquet A; Stoppa-Lyonnet D; Kirova YM; Sigal-Zafrani B; Asselain B; ;
    Am J Clin Oncol; 2009 Apr; 32(2):127-31. PubMed ID: 19307946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer.
    Drooger JC; Heemskerk-Gerritsen BAM; Smallenbroek N; Epskamp C; Seynaeve CM; Jager A
    Breast Cancer Res Treat; 2016 Apr; 156(3):557-566. PubMed ID: 27060914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The incidence of cardiomyopathy in BRCA1 and BRCA2 mutation carriers after anthracycline-based adjuvant chemotherapy.
    Pearson EJ; Nair A; Daoud Y; Blum JL
    Breast Cancer Res Treat; 2017 Feb; 162(1):59-67. PubMed ID: 28066861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers.
    Metcalfe K; Lynch HT; Ghadirian P; Tung N; Kim-Sing C; Olopade OI; Domchek S; Eisen A; Foulkes WD; Rosen B; Vesprini D; Sun P; Narod SA
    Breast Cancer Res Treat; 2011 May; 127(1):287-96. PubMed ID: 21221768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effectiveness of platinum-based chemotherapy in ovarian cancer patients with BRCA1/2 mutations].
    Gorodnova TV; Maksimov SIa; Guseĭnov KD; Imianitov EN
    Vopr Onkol; 2014; 60(3):339-42. PubMed ID: 25033687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
    Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
    Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.
    Graeser MK; Engel C; Rhiem K; Gadzicki D; Bick U; Kast K; Froster UG; Schlehe B; Bechtold A; Arnold N; Preisler-Adams S; Nestle-Kraemling C; Zaino M; Loeffler M; Kiechle M; Meindl A; Varga D; Schmutzler RK
    J Clin Oncol; 2009 Dec; 27(35):5887-92. PubMed ID: 19858402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age.
    Drooger J; Akdeniz D; Pignol JP; Koppert LB; McCool D; Seynaeve CM; Hooning MJ; Jager A
    Breast Cancer Res Treat; 2015 Nov; 154(1):171-80. PubMed ID: 26467044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy.
    Furlanetto J; Möbus V; Schneeweiss A; Rhiem K; Tesch H; Blohmer JU; Lübbe K; Untch M; Salat C; Huober J; Klare P; Schmutzler R; Couch FJ; Lederer B; Gerber B; Zahm DM; Bauerfeind I; Nekljudova V; Hanusch C; Jackisch C; Link T; Hahnen E; Loibl S; Fasching PA
    Eur J Cancer; 2021 Mar; 145():44-52. PubMed ID: 33423006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients.
    Friedlaender A; Vuilleumier A; Viassolo V; Ayme A; De Talhouet S; Combes JD; Peron J; Bodmer A; Giraud S; Buisson A; Bonadona V; Gauchat-Bouchardy I; Tredan O; Chappuis PO; Labidi-Galy SI
    Breast Cancer Res Treat; 2019 Apr; 174(3):775-783. PubMed ID: 30635808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing.
    de la Cruz J; Andre F; Harrell RK; Bassett RL; Arun B; Mathieu MC; Delaloge S; Gilcrease MZ
    Hum Pathol; 2012 Nov; 43(11):1932-9. PubMed ID: 22591913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
    Kirova YM; Stoppa-Lyonnet D; Savignoni A; Sigal-Zafrani B; Fabre N; Fourquet A;
    Eur J Cancer; 2005 Oct; 41(15):2304-11. PubMed ID: 16140006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
    Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
    Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.
    Bignon L; Fricker JP; Nogues C; Mouret-Fourme E; Stoppa-Lyonnet D; Caron O; Lortholary A; Faivre L; Lasset C; Mari V; Gesta P; Gladieff L; Hamimi A; Petit T; Velten M
    Breast J; 2018 May; 24(3):269-277. PubMed ID: 28929593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
    Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
    Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic predisposition to radiation induced sarcoma: possible role for BRCA and p53 mutations.
    Kadouri L; Sagi M; Goldberg Y; Lerer I; Hamburger T; Peretz T
    Breast Cancer Res Treat; 2013 Jul; 140(1):207-11. PubMed ID: 23824362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers.
    Byrski T; Gronwald J; Huzarski T; Grzybowska E; Budryk M; Stawicka M; Mierzwa T; Szwiec M; Wiśniowski R; Siolek M; Narod SA; Lubinski J;
    Breast Cancer Res Treat; 2008 Mar; 108(2):289-96. PubMed ID: 17492376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.